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Summary 
Laboratory testing as a part of laboratory in vitro diagnostic
(IVD) has become required tool in clinical practice for diag-
nosing, monitoring and prognosis of diseases, as well as for
prediction of treatment response. The number of IVD tests
available in laboratory practice has increased over the past
decades and is likely to further increase in the future.
Consequently, there is growing concern about the overuti-
lization of laboratory tests and rising costs for laboratory
testing. It is estimated that IVD accounts for between 1.4
and 2.3% of total healthcare expenditure and less than 5%
of total hospital cost (Lewin Group report). These costs are
rather low when compared to pharmaceuticals and medical
aids which account for 15 and 5%, respectively. On the
other hand, IVD tests play an important role in clinical prac-
tice, as they influence from 60% to 70% of clinical deci-
sion-making. Unfortunately, constant increases in health-
care spending are not directly related to healthcare benefit.
Since healthcare resources are limited, health payers are
interested whether the benefits of IVD tests are actually
worth their cost. Many articles have introduced frameworks
to assess the economic value of IVD tests. The most appro-
priate tool for quantitative assessment of their economic
value is cost-effectiveness (CEA) and cost-utility (CUA)
analysis. The both analysis determine cost in terms of
effectiveness or utilities (combine quantity and quality of
life) of new laboratory test against its alternative. On the
other hand, some investigators recommended calculation
of laboratory test value as product of two ratios: Laboratory
test value = (Technical accuracy/Turnaround time) ×
Kratak sadr`aj
Laboratorijska ispitivanja, kao deo in vitro dijagnostike (IVD),
neophodan su alat u klini~koj praksi za dijagnostiku, pra}enje
i prognozu bolesti, kao i za predvi|anje odgovora na tera piju.
Tokom proteklih nekoliko decenija broj dostupnih IVD testo-
va rastao je postepeno i verovatno }e se takav trend nasta viti
i u budu}nosti. Postoji zabrinutost zbog pove}anog i nera-
cionalnog kori{}enja laboratorijskih testova i shodno tome,
porasta tro{kova za laboratorijsko testiranje. Me|utim, na
osnovu izve{taja Levin Groupe procenjuje se da IVD testovi
~ine manje od 2% tro{kova ukupne zdravstvene za{tite (ZZ)
i manje od 5% bolni~kih tro{kova. Ovi tro{kovi su prili~no
mali u pore|enju sa izdacima za lekove (15%) i me dicinska
pomagala (5%). S druge strane, laboratorijska ispi tivanja
igraju va`nu ulogu u klini~koj praksi, jer omogu}avaju
dono{enje 60% do 70% klini~kih odluka. Na `alost, konstan-
tan porast izdataka u ZZ nije u relaciji sa porastom zdrav -
stvene koristi. Po{to su resursi za ZZ ograni~eni, finansijere u
zdravstvu (fondove zdravstvenih osiguranja) interesuje da li
tro{kovi laboratorijskih testova (posebno novih testova)
oprav davaju dobijenu korist. Preporu~eni su okviri za proce -
nu ekonomske vrijednosti la bo ratorijskih testova. Najpo god -
niji instrumenti za kvantitativno procenu njihove ekonomske
vrednosti su analiza tro{kovne isplativosti (CEA) i analiza
korisnosti tro{kova (CUA). Obe analize procenjuju tro{kove u
odnosu na efektivnost (CEA) ili u odnosu na korist (kombi -
nuje kvantitet i kvalitet `ivota – CUA) laborato rijskog testa
pore|enjem sa alternativom. S druge strane, neki istra`iva~i
preporu~uju izra~unavanje vrednosti laboratorijskog testa iz
proizvoda dva koli~nika: vrednost laboratorijskog testa =
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Introduction
Laboratory in vitro diagnostic (IVD) tests, two-
and three-dimensional imaging and various types of
endoscopy are examples of diagnostic technologies.
They form an integral part of effective healthcare sys-
tems by providing essential information for medical
decision-making, from personalised cancer treatment
to treatment of infections by the appropriate antibiotic
selection (1). IVD tests use samples for example
blood, urine and tissue that have been taken from the
human body in order to assess the potential risk of
developing a disease, monitor disease progression,
treatment response, efficacy of therapy and to medi-
cate patients with specific drugs and therapies (2).
The demand for quicker and more accurate medical
diagnostics, including IVD tests, is rising. Improving
the accuracy and efficiency of testing provides a sub-
stantial contribution to healthcare resource saving. As
a consequence, the number of IVD tests available in
laboratory practice has increased over the past
decades and is likely to further increase in the future. 
It is estimated that IVD accounts for between
1.4 and 2.3% of total healthcare expenditure (3, 4)
and less than 5% of total hospital cost (Lewin Group
report) (5). These costs are rather low when com-
pared to pharmaceuticals and medical aids which
account for 15 and 5%, respectively (6). According to
Serbian Health Insurance Fund data, in 2016 IVD
tests, consumables and medical supplies accounted
for 10% and drugs, pharmaceuticals and medical aids
accounted 21% of total healthcare expenditure,
respectively (7). Despite the fact that laboratory tests
form a very small part of total healthcare expenditure
they exert a great influence on medical decisions (8).
Unfortunately, constant increases in healthcare
spending are not directly related to healthcare bene-
fit. There is a great deal of evidence to suggest that
costs due to over-utilization (9), errors (10), unneces-
sary or inappropriate test utilization and unnecessary
test repetition (11) accounted for expenses much
higher than those due to the direct costs of appropri-
ate laboratory tests (12). In addition, a British study
has estimated that eliminating inappropriate testing
could save the National Health Service up to ₤1 bil-
lion in test costs alone (13). On the other hand, the
growing number of laboratory tests in recent years
has created challenges for physicians and laboratory
professionals to determine the best strategy to diag-
nose disease, monitor disease progression and moni-
tor treatment response. In many cases laboratory pro-
fessionals make choices between two or more
laboratory tests with similar diagnostic importance but
with different associated costs without supporting
data from comparative research studies. An appar-
ently expensive test might turn out to be cost-saving
if it averts costly procedures and/or therapy. Since
healthcare resources are limited, health payers are
interested whether the benefits of IVD tests are actu-
ally worth their cost. 
Problems in implementing economic
evaluation of laboratory testing 
For many years in the European Union only the
CE label was required for diagnostic test registration.
However, in the light of financial constraints third-
party payers need to be sure that CE-labelled diagnos-
tic tests have realistic pricing and/or add true value to
society’s healthcare (14). 
Many articles have introduced frameworks to
assess the economic value of IVD tests. The most
appropriate tool for quantitative assessment of their
economic value is cost-effectiveness (CEA) and cost-
utility (CUA) analysis. Both analyses compare the
costs and effectiveness/utility of two or more health
interventions, for example IVD tests (15). Potential
usefulness from IVD testing is early and accurate
diagnosis, appropriate patient selection for therapy
and consequently increasing patients’ life expectancy
and quality of life. Therefore, utility in CUA is fre-
quently expressed as quality-adjusted life-years
(QALY) (15). Unfortunately, this value is rarely avail-
able for IDV tests. In cross-sectional or cohort studies
test accuracy is the most accessible value. However,
(Utility/Costs). Recently, some researches used multicriteria
decision analysis which allows comparison of diagnostic
strategies in terms of benefits, opportunities, costs and
risks. All analyses are constructed to identify laboratory test
that produce the greatest healthcare benefit with the
resources available. Without solid evidence that certain lab-
oratory tests are cost-effective, laboratory services cannot
be improved. Consequently, simple policy measures such
as cost cutting may be imposed upon many laboratories
while patients will have limited access to laboratory service.
Keywords:  laboratory tests, cost-effectiveness, cost -
utility, multicriteria decision analysis
(ta~nost / TAT) × (klini~ka korist / tro{kovi). Poslednjih neko-
liko godina preporu~uje se i ana liza vi{ekriterijumskog
dono{enja odluka koja omogu}ava po re|enje dijagnosti~kih
strategija u smislu korisnosti, mo gu} nosti, tro{kova i rizika.
Ove analize mogu da identifikuju laboratorijski test koji ima
najve}u zdravstvenu korist za raspolo`iva sredstva. Bez
dokaza da su laboratorijski testovi isplativi u smislu efekata i
tro{kova, kori{}enje laboratorijskih usluga ne mo`e se una -
prediti. Posledi~no, mogu biti primenjene mere kao {to su
smanjeno finansiranje laboratorija, a pacijenti }e imati ogra -
ni~en pristup laboratorijskim uslugama.
Klju~ne re~i: laboratorijski testovi, analiza tro{kovne ispla-
tivosti, analiza korisnosti tro{kova, analiza vi{ekriterijumskog
dono{enja odluka 
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this value is a surrogate for patient-important out-
comes, as studies often provide low quality evidence
for IVD test utility (16). In addition, decision makers
face problems in interpreting diagnostic accuracy. It is
necessary to present and interpret the results so that
clinicians, policy makers, consumers and other re -
searchers can perfectly understand them. In such sit-
uations, Van den Bruel and colleagues recommended
an investigation into the test’s influence on physi-
cians’ opinions about diagnosis (17). Such evidence
may be used for CEA of IVD tests in an early stage of
an investigation. On the other hand, utility value
should also be determined by expert elicitations (18).
An additional problem in IVD economic evalua-
tion by CEA and CUA is lack of an appropriate thresh-
old value. An intervention is considered to be “cost-
effective” if the cost effectiveness ratio is below the
threshold (19). However, it is difficult to estimate the
thresholds at which IVD tests are effective enough to
justify funding. The UK National Institute for Health
and Care Excellence (NICE) recently recommended
cost-effectiveness threshold in a range from £20,000
to £30,000 per QALY for drugs (20). Unfortunately,
this threshold massively exceeds the cost of conven-
tional diagnostic testing (21). Alternatively, in low and
middle income countries the World Health Orga -
nization (WHO) has recommended thresholds of 1 to
3 times the gross domestic product per capita (22).
However, the consequence of threshold use, if it is an
inappropriate measure of the health cost, is that
thresholds are likely to reduce, rather than increase,
population health. Up to now CEA and CUA have
only been employed towards a limited number of
diagnostics. 
Additional recommendations for 
laboratory test economic evaluation
To avoid such a problem, calculation of labora-
tory test value as a product of two ratios, test per-
formance and efficiency has been recommended by
Equation:
Laboratory test value = (Technical accuracy/
Turnaround time) × (Utility/Costs) 
Good test performance is associated with high
accuracy and low turnaround time, while high effi-
ciency is associated with a high percentage of clinical
decisions made (clinical utility) over costs. In this case
utility represents the most accurate conclusion given
the available evidence for a diagnostic test (23). 
In addition, healthcare decisions should be
based on a broad range of variables that are not part
of the CEA, CUA or laboratory test value model such
as clinical accuracy, number of both false and true
positive and negative values, priorities, accessibility
and ease of use (24). In the laboratory/hospital con-
text multiple criteria should be considered simultane-
ously when deciding whether or not to adopt a new
laboratory test. Recently, some investigators have
used multi-criteria decision analysis (MCDA) method-
ology. In MCDA each criterion is scored and weighted
(25). Scores represent ranked alternatives for each
criterion. Weights for each of the criteria reflect their
relative importance to the decision. They represent
the opinion of a single decision maker or combine
opinions of a group of experts. A mathematical equa-
tion combines these two components and the result is
overall weighted scores that provide an overall assess-
ment of each alternative, Table I (25). MCDA distin-
guishes acceptable from unacceptable laboratory
tests. It is a tool that goes beyond cost-effectiveness
by allowing complex integration of more factors (26). 
Examples of laboratory test economic
evaluation
The goal of an effective and efficient laboratory
is to identify laboratory tests that create the greatest
healthcare benefit with the resources available. In
addition, overuse, underuse and misuse of laboratory
testing should be minimized. An example of cost-
effective laboratory test selection was described by
Petrovic and coworkers (27). They created the deci-
Alternative 1 Alternative 2 Alternative v
Weight1 Criterion 1 S11 / S1v
Weight2 Criterion 2 / / /
Weighte Criterion i Si1 / S1v
OWF1 OWF2 OWFn
Table I Multi-criteria decision table.
Criterion1 – Criterioni (rows) and Alternative 1 – Alternative v (columns) represent the criteria and alternatives, respectively. The
score Siv describes the performance of Alternativev against Criteriai. A higher score value means a better performance. Weight1
– Weight e reflect the relative importance of Criteria i to the decision. The overall weighted scores (OWF) are the final ranking val-
ues of the alternatives. The alternative with the highest OWF value is the best of the alternatives.
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sion analytical model to describe different strategies
for acute kidney injury diagnosis in children after car-
diac surgery using monitoring of creatinine (standard
monitoring) and new biomarkers [serum cystatin C
(sCys C), urine neutrophil gelatinase-associated
lipocalin (uNGAL) and urine liver fatty acid-binding
protein (uL-FABP)]. Tests for uNGAL and sCys C were
associated with higher costs and lower effectiveness
compared to uL-FABP. The use of uL-FABP would like-
ly represent an economically advantageous strategy
for early diagnosis of child acute kidney injury after
cardiac surgery. Another example of CEA application
by laboratory professionals as a tool for avoiding inap-
propriate test utilization examined the cost-effective-
ness of two different strategies for screening of deep
vein thrombosis (DVT) with three different D-dimer
assays (Innovance D-dimer, Hemosil D-dimer HS and
Vidas D-dimer Exclusion II) (28). One strategy includ-
ed assesment of clinical probability for DVT (PTP) and
another strategy excluded PTP assessment. CEA indi-
cated an advantage of D-dimer measurements in
combination with PTP assessment over D-dimer
measurements without PTP. For laboratories assessing
high numbers of DVT patients, the best cost-effective-
ness ratio was for the diagnostic strategy which
employed the Vidas D-dimer Exclusion II assay. In
contrast, the Hemosil D-dimer HS assay was the most
cost effective strategy for laboratories with a small
number of DVT patients. 
Conclusion
In summary, IVD testing can reduce both direct
and indirect healthcare costs if it results in more accu-
rate and timely medical diagnoses. However, without
solid evidence that certain laboratory tests are cost-
effective, laboratory services cannot be improved.
Harsh across-the-board cost cutting of laboratory ser-
vices will limit the diagnoses of patients as a reduced
number of tests will be available. Therefore, deter-
mining cost-effectiveness prior to cost cutting is much
more logical but requires extensive education of both
laboratory professionals and non-clinical laboratory
staff in order to determine which tests will remain and
which will be omitted from the laboratory test portfo-
lio.
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